1189980-63-9
Chemical Structure
Methsuximide-d5
- CAS No.: 1189980-63-9
- Formula:C12H8D5NO2
- Molecular Weight:208.27
IUPAC Name: 1,3-dimethyl-3-(phenyl-d5)pyrrolidine-2,5-dione
InChIKey: AJXPJJZHWIXJCJ-DKFMXDSJSA-N
SMILES: CC1(C(=O)N(C)C(=O)C1)C2=C(C(=C(C(=C2[2H])[2H])[2H])[2H])[2H]
Biological Activity: Methsuximide-d5 is the deuterated-labeled Methsuximide (HY-B1376). Methsuximide (Mesuximide) is an orally active succinimide-derived antiepileptic agent. Methsuximide interacts with cytochrome P-450, increases the level of hepatic microsomal cytochrome P-450, and inhibits or competes with the cytochrome P-450 CYP 2C9/10 subtype. Methsuximide can be used in epilepsy-related research[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Methsuximide-d5 | Methsuximide-d5 is the deuterated-labeled Methsuximide (HY-B1376). Methsuximide (Mesuximide) is an orally active succinimide-derived antiepileptic agent. Methsuximide interacts with cytochrome P-450, increases the level of hepatic microsomal cytochrome P-450, and inhibits or competes with the cytochrome P-450 CYP 2C9/10 subtype. Methsuximide can be used in epilepsy-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Methsuximide (Standard) | ≥98% | Methsuximide (Standard) (Mesuximide (Standard); Celontin (Standard)) is the analytical standard of Methsuximide (HY-B1376). This product is intended for research and analytical applications. Methsuximide (Mesuximide) is an orally active succinimide-derived antiepileptic agent. Methsuximide interacts with cytochrome P-450, increases the level of hepatic microsomal cytochrome P-450, and inhibits or competes with the cytochrome P-450 CYP 2C9/10 subtype. Methsuximide can be used in epilepsy-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Methsuximide | 99.68% | Methsuximide (Mesuximide) is an orally active succinimide-derived antiepileptic agent. Methsuximide interacts with cytochrome P-450, increases the level of hepatic microsomal cytochrome P-450, and inhibits or competes with the cytochrome P-450 CYP 2C9/10 subtype. Methsuximide can be used in epilepsy-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Orton TC, et al. Effect in rats of subacute administration of ethosuximide, methsuximide and phensuximide on hepatic microsomal enzymes and porphyrin turnover. Biochem Pharmacol. 1972 Aug 15;21(16):2253-61.
- [2]. CHEN G, et al. Anticonvulsant activity and toxicity of phensuximide, methsuximide and ethosuximide. Epilepsia. 1963 Mar;4:66-76.
- [3]. Sigler M, et al. Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood. Seizure. 2001 Mar;10(2):120-4.
- [4]. Besag FM, et al. Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7.
- [5]. Dobrinska MR, et al. Pharmacokinetics of methsuximide and a major metabolite in dogs. Journal of pharmaceutical sciences. 1977 May;66(5):688-92.
